{"id":"chlortetracycline-hydrochloride","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"drugInteractions":[{"drug":"Antacids containing aluminum, calcium, or magnesium","interaction":"Reduces absorption of chlortetracycline"},{"drug":"Iron supplements","interaction":"Reduces absorption of chlortetracycline"},{"drug":"Oral contraceptives","interaction":"May decrease effectiveness of oral contraceptives"}],"commonSideEffects":[{"effect":"Nausea","drugRate":"10%","severity":"Mild"},{"effect":"Vomiting","drugRate":"5%","severity":"Mild"},{"effect":"Diarrhea","drugRate":"8%","severity":"Mild"},{"effect":"Photosensitivity","drugRate":"3%","severity":"Moderate"},{"effect":"Tooth discoloration","drugRate":"2%","severity":"Severe"}],"contraindications":["Hypersensitivity to tetracyclines","Use in children under 8 years of age due to the risk of permanent tooth discoloration"],"specialPopulations":{"Geriatric":"Use with caution; monitor for renal function","Lactation":"Excreted in breast milk; use with caution","Pediatric":"Not recommended for children under 8 years due to the risk of tooth discoloration","Pregnancy":"Category D: Risk to the fetus has been observed in humans"}},"trials":[],"_chembl":null,"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[{"date":"1948","type":"Approval","milestone":"First approved by FDA","regulator":"FDA"}],"_dailymed":{"setId":"005a4179-b650-4c00-a59c-3ca2ab3c95f5","title":"AUREOMYCIN (CHLORTETRACYCLINE HYDROCHLORIDE) GRANULE [PHIBRO ANIMAL HEALTH]"},"aiSummary":"Chlortetracycline hydrochloride is an older broad-spectrum antibiotic that belongs to the tetracycline class. It is primarily used for treating bacterial infections, but due to its age and the availability of newer antibiotics, it is less commonly prescribed today. The drug works by inhibiting bacterial protein synthesis, making it effective against a wide range of Gram-positive and some Gram-negative bacteria. Despite its efficacy, chlortetracycline has several limitations, including potential side effects and the risk of bacterial resistance. Its use is generally reserved for specific cases where other antibiotics may not be suitable.","ecosystem":[],"mechanism":{"target":"30S ribosomal subunit","novelty":"Older, well-established antibiotic","modality":"Small molecule","drugClass":"Tetracycline","explanation":"The drug interferes with the bacterial ribosome's ability to synthesize proteins, which are essential for bacterial growth and survival.","oneSentence":"Chlortetracycline hydrochloride inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the ribosome.","technicalDetail":"Chlortetracycline binds to the 30S ribosomal subunit, specifically at the A site, where it blocks the binding of aminoacyl-tRNA, thereby halting the elongation step of protein synthesis."},"_scrapedAt":"2026-03-28T00:39:13.333Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"yoyGrowth":"N/A","launchDate":"N/A","annualCostUS":"N/A","currentRevenue":"N/A","patientPopulation":"Limited, primarily for specific bacterial infections","peakSalesEstimate":"N/A"},"references":[],"biosimilars":[],"competitors":["Doxycycline","Minocycline","Oxytetracycline"],"indications":{"approved":["Bacterial infections"],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[],"_emaApprovals":[],"_faersSignals":[{"count":4,"reaction":"DYSKINESIA"},{"count":4,"reaction":"THERAPY CHANGE"},{"count":2,"reaction":"ACUTE KIDNEY INJURY"},{"count":2,"reaction":"ANAEMIA"},{"count":2,"reaction":"CHRONIC KIDNEY DISEASE"},{"count":2,"reaction":"CONDITION AGGRAVATED"},{"count":2,"reaction":"DECREASED APPETITE"},{"count":2,"reaction":"DIZZINESS"},{"count":2,"reaction":"HEPATIC FUNCTION ABNORMAL"},{"count":2,"reaction":"PANCREATITIS"}],"genericFilers":["Mylan","Teva","Sandoz"],"latestUpdates":[],"manufacturing":[],"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":122,"therapeuticAreas":["Infectious Disease"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"approved","brandName":"CHLORTETRACYCLINE HYDROCHLORIDE","genericName":"CHLORTETRACYCLINE HYDROCHLORIDE","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"1950","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}